|Other Names||NF-kappa-B essential modulator, NEMO, IkB kinase-associated protein 1, IKKAP1, mFIP-3, Inhibitor of nuclear factor kappa-B kinase subunit gamma, I-kappa-B kinase subunit gamma, IKK-gamma, IKKG, IkB kinase subunit gamma, NF-kappa-B essential modifier, Ikbkg, Nemo|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP3129a was selected from the region of human Mouse Phospho-IKKg-S375. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B- mediated protection from cytokine toxicity. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination.|
|Cellular Location||Cytoplasm. Nucleus|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IKKg is a regulatory subunit part of the IKK-signalosome complex activation. It is also considered to be a mediator for TAX activation of NF-kappa-B. Additionally, this protein could be implicated in NF-kappa-B-mediated protection from cytokine toxicity.
J. Cereb. Blood Flow Metab. 25 (10), 1301-1311 (2005)J. Clin. Invest. 115 (4), 849-859 (2005)J. Biol. Chem. 279 (52), 54248-54257 (2004)Mol. Cells 18 (2), 200-206 (2004)Proc. Natl. Acad. Sci. U.S.A. 100 (3), 1203-1208 (2003)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.